Hangzhou KBM Life sciences Co.,Ltd
Human CYP3A5 Genotyping Detection Kit (Fluorescence-PCR Method)
As the first fluorescent quantitative PCR method in the country
CYP3A5 gene polymorphism detection product,
After original research and development,
Conduct clinical trials and registration review in accordance with Class III products,
It took three years,
Finally passed the review by the National Market Supervision and Administration Bureau，
Obtained the three-class medical device registration certificate!
CYP3A5 participates in the metabolism of nifedipine, tacrolimus, midazolam, dapsone and other drugs.
Nifidipine belongs to the class of antihypertensive drugs calcium channel blockers (CCB). CCB is the only drug that can be used in combination with the other four major antihypertensive drugs, and it plays an important role in hypertension antihypertensive drugs! Tacrolimus is a macrolide immunosuppressant, which is widely used clinically in the immunosuppressive treatment of liver, kidney, heart, lung, pancreas and other organ transplant patients.
There is a 6986A>G mutation (rs776746, CYP3A5*3) at position 22893 in the third intron of the CYP3A5 gene. This SNP can lead to abnormal splicing of CYP3A5 mRNA, causing the stop codon to cleave the CYP3A5 protein prematurely, thereby causing it to lose enzyme activity Therefore, the expression and activity of CYP3A5 protein in the liver and intestine of CYP3A5*3 homozygous individuals were significantly decreased.
kmb Developed an advanced fluorescent PCR method,
Detection of CYP3A5 gene polymorphism。
Fluorescent PCR platform adopts
Dual-probe system fluorescence-PCR technology,
The detection efficiency is twice as high as ordinary fluorescent PCR,
The cost of reagents can be reduced by 30%-50%.